KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2023 - 2025)

Biocryst Pharmaceuticals' Capital Expenditures history spans 9 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 256.74% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $608000.0, down 45.91%, while the annual FY2025 figure was $608000.0, 45.91% down from the prior year.
  • Capital Expenditures reached -$1.1 million in Q4 2025 per BCRX's latest filing, down from $597000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $987000.0 in Q3 2023 to a low of -$1.6 million in Q4 2023.
  • Average Capital Expenditures over 3 years is $144333.3, with a median of $197500.0 recorded in 2023.
  • The largest YoY upside for Capital Expenditures was 911.86% in 2025 against a maximum downside of 256.74% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at -$1.6 million in 2023, then soared by 141.82% to $675000.0 in 2024, then tumbled by 256.74% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Capital Expenditures are -$1.1 million (Q4 2025), $597000.0 (Q3 2025), and $926000.0 (Q2 2025).